US 11,939,635 B2
Treatment of obesity in subjects having variant nucleic acid molecules encoding Calcitonin Receptor (CALCR)
Luca Andrea Lotta, Tarrytown, NY (US); Parsa Akbari, Tarrytown, NY (US); Manuel Allen Revez Ferreira, Tarrytown, NY (US); and Aris Baras, Tarrytown, NY (US)
Assigned to Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed by Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed on Aug. 13, 2021, as Appl. No. 17/401,679.
Claims priority of provisional application 63/108,308, filed on Oct. 31, 2020.
Claims priority of provisional application 63/066,182, filed on Aug. 15, 2020.
Prior Publication US 2022/0049308 A1, Feb. 17, 2022
Int. Cl. C12Q 1/68 (2018.01); C12P 19/34 (2006.01); C12Q 1/6883 (2018.01)
CPC C12Q 1/6883 (2013.01) [C12Q 2600/118 (2013.01); C12Q 2600/156 (2013.01)] 20 Claims
 
1. A method of treating a subject with a therapeutic agent that treats or inhibits obesity and/or reduces body mass index (BMI), wherein the subject has obesity and/or increased BMI, the method comprising the steps of:
determining whether the subject has a Calcitonin Receptor (CALCR) variant nucleic acid molecule encoding a CALCR predicted loss-of-function polypeptide by:
obtaining or having obtained a biological sample from the subject; and
performing or having performed a sequence analysis on the biological sample to determine if the subject has a genotype comprising the CALCR variant nucleic acid molecule; and
administering or continuing to administer to the subject the therapeutic agent that treats or inhibits obesity and/or increased BMI in a standard dosage amount to a subject that is CALCR reference and does not have a copy of a CALCR variant nucleic acid molecule encoding a CALCR predicted loss-of-function polypeptide; or
administering or continuing to administer to the subject the therapeutic agent that treats or inhibits obesity and/or increased BMI in an amount that is the same as or greater than a standard dosage amount to a subject that is heterozygous or homozygous for the CALCR variant nucleic acid molecule; and
wherein the CALCR predicted loss-of-function polypeptide comprises S18P, R92C, K125fs, I178V, S209N, R355Q, F390V, V392I, A422V, R432C, S456F, R461fs, or N487fs.